An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A recent roundup in BusinessWorld Online from December 2025 talked about the latest news around two widely talked-about weight-loss medicines: semaglutide and tirzepatide. The piece summarized regulatory updates, sales and availability, and some new study results that have come out this year. It wasn’t a single dramatic discovery so much as a status update showing these drugs are becoming more common and are continuing to be studied. Semaglutide and tirzepatide are drugs that act like natural hormones your gut makes after you eat. Semaglutide mimics a hormone that helps you feel full and slows how fast food leaves your stomach. Tirzepatide does something similar but hits two different hormone systems at once, which may make the full feeling stronger. People usually get them as injections and they’re prescribed for chronic weight management or diabetes; you may have heard semaglutide called Ozempic or Wegovy and tirzepatide sold under names like Zepbound or Mounjaro depending on the use and country. The reporting covered several kinds of findings: ongoing clinical trials, real-world prescribing trends, and company announcements. Some newer trials out to December 2025 show continued average weight losses that are meaningful for many people — often in the teens of percent body weight for people who stay on treatment — and head-to-head comparisons suggesting tirzepatide can produce slightly larger average losses than semaglutide in some studies. But the article also noted that most of the strongest evidence comes from controlled clinical trials or large observational datasets, and results can vary a lot between individuals. It didn’t present new, single definitive studies overturning earlier evidence; instead it reinforced a pattern seen over recent years. Why this matters is practical: these medicines are changing how doctors and patients approach obesity and diabetes. For people struggling with weight-related health problems, they can offer a tool that often produces bigger and faster weight loss than older approaches. That can improve blood sugar, blood pressure and other health markers. The reporting also highlighted how growing demand affects access and cost — people who might benefit could face waiting lists or insurance limits. There are important caveats and risks. Common side effects include nausea, diarrhea and constipation, especially early on. Serious but rare problems can occur, and long-term effects beyond a few years are still being studied. Stopping the drugs usually leads to some weight regain unless other lifestyle or medical measures are used. They are prescription medicines, not over-the-counter supplements, and they aren’t appropriate for everyone — for example, people with certain medical histories need careful evaluation. Regulatory approvals and recommended uses differ by country, so availability depends on where you live. Bottom line: Semaglutide and tirzepatide remain effective tools for weight and metabolic care, with new studies and wider use through 2025 reinforcing their role — but they come with side effects, access issues, and unanswered long-term questions.
Source: BusinessWorld Online